Announced Date: 2022-06-13 ( June 13, 2022)
Asset Name: Perjeta® (pertuzumab, HLX11) and Prolia®/Xgeva® (denosumab, HLX14).
Licensor: Shanghai Henlius Biotech (China)
Licensee (Buyer): Organon
.
Asset Detail:
HLX11 (anti-HER2 domain II humanized monoclonal antibody injection) is a biosimilar candidate of pertuzumab.
HLX14 (recombinant anti-RANKL human monoclonal antibody injection) is a biosimilar candidate of denosumab.
Pertuzumab is used for the treatment of certain patients with HER2+ breast cancer in combinations with trastuzumab and chemotherapy.
Denosumab is used for the treatment of certain patients with osteoporosis with high risk of fracture and for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastasis from solid tumors.
.
Scope of Authority:
Organon will license commercialization rights for biosimilar candidates referencing Perjeta® (pertuzumab, HLX11) and Prolia®/Xgeva® (denosumab, HLX14).
Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan.
.
Payment Detail:
The transaction includes an upfront payment of $73 million as well as additional payments upon the achievement of certain development, regulatory and commercial milestones. Total up to $541 million.
Henlius will be responsible for development and, if approved, will supply the products to Organon.
.
Link:
.
Note:
Shanghai Henlius Biotech (Chinese Name: 上海复宏汉霖
